Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Touchon Pascal | President and CEO | Aug 16 | Sale | 5.04 | 14,806 | 74,548 | 457,287 | Aug 18 06:24 PM | Dupont Jakob | EVP, Head of R&D | Aug 16 | Sale | 5.03 | 4,124 | 20,760 | 158,882 | Aug 18 06:21 PM | Murugan Amar | SVP, GC & Secretary | Aug 16 | Sale | 5.03 | 3,430 | 17,269 | 131,198 | Aug 18 06:21 PM | Koppikar Utpal | Chief Financial Officer | Aug 16 | Sale | 5.04 | 5,940 | 29,908 | 197,589 | Aug 18 06:20 PM | Touchon Pascal | President and CEO | Jun 27 | Sale | 7.20 | 14,220 | 102,384 | 472,093 | Jun 29 04:48 PM | Koppikar Utpal | Chief Financial Officer | Jun 08 | Sale | 5.63 | 5,853 | 32,952 | 203,529 | Jun 10 04:20 PM | Murugan Amar | SVP, GC & Secretary | May 17 | Sale | 5.32 | 3,223 | 17,134 | 133,735 | May 19 05:20 PM | Koppikar Utpal | Chief Financial Officer | May 17 | Sale | 5.32 | 5,582 | 29,675 | 207,592 | May 19 05:16 PM | Dupont Jakob | EVP, Head of R&D | May 17 | Sale | 5.32 | 3,873 | 20,597 | 163,006 | May 19 05:08 PM | Touchon Pascal | President and CEO | May 17 | Sale | 5.32 | 13,913 | 73,962 | 486,313 | May 19 05:04 PM | Dupont Jakob | EVP, Head of R&D | Mar 01 | Sale | 9.86 | 2,221 | 21,890 | 166,879 | Mar 03 07:02 PM | Koppikar Utpal | Chief Financial Officer | Mar 01 | Sale | 9.86 | 3,763 | 37,090 | 213,174 | Mar 03 07:02 PM | Murugan Amar | SVP, GC & Secretary | Mar 01 | Sale | 9.86 | 2,577 | 25,400 | 136,958 | Mar 03 07:02 PM | Touchon Pascal | President and CEO | Mar 01 | Sale | 9.86 | 8,828 | 87,009 | 500,226 | Mar 03 07:02 PM | Dupont Jakob | EVP, Head of R&D | Feb 10 | Option Exercise | 9.58 | 5,000 | 47,900 | 95,594 | Feb 14 05:42 PM | Dupont Jakob | EVP, Head of R&D | Feb 10 | Sale | 16.00 | 5,000 | 80,000 | 90,594 | Feb 14 05:42 PM | Koppikar Utpal | Chief Financial Officer | Feb 07 | Sale | 14.46 | 2,496 | 36,096 | 155,702 | Feb 09 04:35 PM | Dupont Jakob | EVP, Head of R&D | Jan 03 | Option Exercise | 9.58 | 5,000 | 47,900 | 95,594 | Jan 05 04:47 PM | Dupont Jakob | EVP, Head of R&D | Jan 03 | Sale | 16.01 | 5,000 | 80,050 | 90,594 | Jan 05 04:47 PM | Dupont Jakob | EVP, Head of R&D | Dec 01 | Option Exercise | 9.58 | 5,000 | 47,900 | 95,594 | Dec 03 04:15 PM | Dupont Jakob | EVP, Head of R&D | Dec 01 | Sale | 17.94 | 5,000 | 89,688 | 90,594 | Dec 03 04:15 PM | Newell Joe | Chief Operations Officer | Nov 16 | Sale | 17.12 | 3,332 | 57,034 | 113,097 | Nov 18 05:54 PM | Touchon Pascal | President and CEO | Nov 16 | Sale | 17.12 | 8,402 | 143,816 | 328,489 | Nov 18 05:55 PM | Murugan Amar | SVP, GC & Secretary | Nov 16 | Sale | 17.12 | 2,124 | 36,356 | 87,540 | Nov 18 05:53 PM | Dupont Jakob | EVP, Head of R&D | Nov 16 | Sale | 17.12 | 2,199 | 37,640 | 90,594 | Nov 18 05:52 PM | Koppikar Utpal | Chief Financial Officer | Nov 16 | Sale | 17.12 | 3,655 | 62,562 | 157,714 | Nov 18 05:53 PM | Newell Joe | Chief Operations Officer | Nov 15 | Option Exercise | 12.15 | 3,500 | 42,525 | 123,429 | Nov 17 04:15 PM | Newell Joe | Chief Operations Officer | Nov 15 | Sale | 17.71 | 7,000 | 124,004 | 116,429 | Nov 17 04:15 PM | Fust Matthew K | Director | Nov 04 | Sale | 19.50 | 13,354 | 260,403 | 31,500 | Nov 05 04:28 PM | Dupont Jakob | EVP, Head of R&D | Nov 02 | Option Exercise | 9.58 | 5,000 | 47,900 | 97,793 | Nov 04 04:10 PM | Dupont Jakob | EVP, Head of R&D | Nov 02 | Sale | 16.41 | 5,000 | 82,050 | 92,793 | Nov 04 04:10 PM | Newell Joe | Chief Operations Officer | Sep 22 | Option Exercise | 12.15 | 10,500 | 127,575 | 130,429 | Sep 24 05:35 PM | Newell Joe | Chief Operations Officer | Sep 22 | Sale | 17.00 | 10,500 | 178,500 | 119,929 | Sep 24 05:35 PM | Newell Joe | Chief Operations Officer | Sep 15 | Sale | 15.61 | 3,116 | 48,647 | 119,929 | Sep 17 04:36 PM | Newell Joe | Chief Operations Officer | Aug 30 | Sale | 15.00 | 3,500 | 52,500 | 123,045 | Aug 31 05:05 PM |
|